Facebook Twitter

How much will the COVID-19 vaccine cost? Some companies want to skip profit

At least two of the companies developing the COVID-19 vaccine want to skip profits

SHARE How much will the COVID-19 vaccine cost? Some companies want to skip profit
In this handout photo released by the University of Oxford samples from coronavirus vaccine trials are handled inside the Oxford Vaccine Group laboratory in Oxford, England Thursday June 25, 2020.

In this handout photo released by the University of Oxford samples from coronavirus vaccine trials are handled inside the Oxford Vaccine Group laboratory in Oxford, England, on Thursday June 25, 2020.

Associated Press

At least two companies developing the COVID-19 vaccine hope to limit profits, setting a single price for the entire world to pay, USA Today reports.

Five pharmaceutical companies who are developing the vaccine —  AstraZeneca, Johnson & Johnson, Merck, Moderna and Pfizer — will speak with a House subcommittee on Tuesday about their progress on the vaccine, where they are expected to reveal information about cost and availability of the coronavirus vaccine.

AstraZeneca said it will create two billion doses of the vaccine on a nonprofit plan, according to a statement from Executive Vice President Menelas Pangalos.  

Similarly, Johnson & Johnson plans to charge one price for the entire world — in spite of country and income tier, according to a statement from Dr. Macaya Douoguih, head of clinical development and medical affairs.

The vaccine would be available on a  ”not-for-profit basis for emergency pandemic use.”

Companies continue to make progress on a potential COVID-19 vaccine, as I’ve written about for Deseret.com. On Monday, Oxford Universitysaid its potential coronavirus vaccine created a strong immune response, which was seen as a positive sign for the future of the vaccine to stop COVID-19.

  • “It looks like both give useful immune responses even though after two doses we see stronger immune responses. And to keep following these individuals and start trials elsewhere. Hopefully in the U.S. in the next few weeks.”